The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518280-35-00

Acronym

NL83212.091.22

Enrollment

Registered

2025-01-17

Start date

2024-03-26

Completion date

Unknown

Last updated

2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Brief summary

Insomnia Severity Index (ISI) questionnaire

Detailed description

Diary with sleep-related outcomes (Sleep Onset Latency (SOL), number of awakenings (NA), Wake time After Sleep Onset (WASO), Total Sleep Time (TST), and Sleep Efficiency (SE)), Daily recorded non-sleep outcomes are number of nocturnal voiding and potentially occurring adverse events (AEs)., Neurokeys app, The questionnaires ESS, FSS, and CIS-F

Interventions

DRUGInvestigational placebo

DRUGClinican CBD 10% oil

DRUGRun-in placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Insomnia Severity Index (ISI) questionnaire	—

Secondary

Measure	Time frame
Diary with sleep-related outcomes (Sleep Onset Latency (SOL), number of awakenings (NA), Wake time After Sleep Onset (WASO), Total Sleep Time (TST), and Sleep Efficiency (SE)), Daily recorded non-sleep outcomes are number of nocturnal voiding and potentially occurring adverse events (AEs)., Neurokeys app, The questionnaires ESS, FSS, and CIS-F	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026